PTO/SB/08 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCI
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid
OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known		
				Application Number	10/581,990	
				Filing Date	2/26/2007	
	Data Submitted:Se	ntami	hor 1 2010	First Named Inventor	Himanshu BRAHMBHATT	
Date Submitted: September 1, 2010				Art Unit	1632	
(use as many sheets as necessary)			necessary)	Examiner Name	Anoop Kumar SINGH	
Sheet	1	of	2	Attorney Docket Number	060348-0145	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where publisher. (by where publisher).	,
	F1	Letter from Knobbe Martens Olson & Bear LLP dated February 26, 2010.	Г
	F2	Manisha P. DESAI et al., "The Mechanism of Uptake of Biodegradable Microparticles in Caco-2 Cells Is Size Dependent", Pharmaceutical Research, Vol. 14, No. 11, 1997, pp. 1568-1573.	
	F3	Igor DMITRIEV et al., "Ectodomain of Coxsackievirus and Adenovirus Receptor Genetically Fused to Epidermal Growth Factor Mediates Adenovirus Targeting to Epidermal Growth Factor Receptor-Positive Cells", Journal of Virology, Aug. 2000, Vol. 74, No. 15, pp. 6875—6884.	
	F4	Christoph MAMOT et al., "Epidermal Growth Factor Receptor (EGFR)-targeted immunoliposomes Mediate Specific and Efficient Drug Delivery to EGFR- and EGFRVIII-overexpressing Tumor Cells", Cancer Research, June 2003, Vol. 63, 3154—3161.	
	F5	William F. SCHERER M.D. et al., "THE VIRAL RANGE IN VITRO OF A MAUGNANT HUMAN EPITHELIAL CELL (STRAIN HELA, GEY) – III. Studies with Pseudolymphocytic Chorlomeningitus Virus General Discussion", American Journal of Pathology, Jan-Feb 31(1): 31–39 (1954).	
	F6	Masahisa WATARAI et al., "Interaction of Ipa Proteins of Shigella flexneri with αsβι Integrin Promotes Entry of the Bacteria Into Mammalian Cells", J. Exp. Med. Vol. 183, March 1996, pp. 991—999.	
	F7	Tibor PAL et al., "Plasmid-Associated Adherence of <i>Shigella flexneri</i> in a HeLa Cell Model", INFECTION AND IMMUNITY, Aug 1989, Vol. 57, No. 8, pp. 2580—2582.	T
	F8	William F. SCHERER et al., "STUDIES OF THE PROPAGATION IN VITRO OF POLIOMYELITIS VIRUSES", Journal of Experimental Medicine, Vol. 97, No. 5, pp. 695—710 (1953).	
	F9	Aline JAFFE et al., "Minicell-Forming Mutants of Escherichia coli: Production of Minicells and Anucleate Rods", Journal of Bacteriology, Vol. 170, No. 7, July 1988, pp. 3094—3101.	
	F10	Thomas L HALE et al., "Characterization of Virulence Plasmids and Plasmid-Associated Outer Membrane Proteins in Shigella flexaeri, Shigella sonnei, and Escherichia coll", infection and Immunity, April 1983, Vol. 40, No. 1, pp. 340—350.	
	F11	Gary J. DOHERTY et al., "Mechanisms and Endocytosis", Annu. Rev. Biochem. March 14, 2009,78:31.1-31.46.	Г
	F12	Pascal PESCHARD, "Escape from Cbl-mediated downregulatation: A recurrent theme for oncogenic deregulation of receptor tyrosine kinases", CANCER CELL, June 2003, Vol. 3, pp. 519—523.	
	F13	Emmanouil D. KARAGIANNIS et al., "Minicells overcome tumor drug-resistance", NATURE BIOTECHNOLOGY, Vol. 27, No. 7, July 2009, pp. 620—621.	Γ

Examiner	Date	
Signature	Considered	

EXAMINE: Initial If elerence considered, whether or not classon is nonformance with MEPE 989. Daw line through classor is nonformance and not considered broade copy of the form which need communication is paginant. If applicant is usually classed designation number of optional, 22 See Michael Codes of USPTO Patient Documents at www.uspto.gov or WEPE 901.04. 3 Enter Office that issued the document, by the low-bittle code (WIPO Standard ST.3. 4 For Japanese patient documents, but indicated not the year of the region of the Emperor must precede the result number of the placet documents. Office of documents they despond the special control of the placet of the placet

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid

Substitute for form 1449/PTO			C	Complete if Known		
INFORM	ATION DISC	LOSURE	Application Number	10/581,990		
STATEN	IENT BY APP	PLICANT	Filing Date	2/26/2007		
Date Subm	itted:Septem	hor 1 2010	First Named Inventor	Himanshu BRAHMBHATT		
Date Subii	illeu.Sepleiii	Dei 1, 2010	Art Unit	1632		
(use as many sheets as necessary)			Examiner Name	Anoop Kumar SINGH		
Sheet 2	of	2	Attorney Docket Number	060348-0145		

		NON PATENT LITERATURE DOCUMENTS	-
examiner nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	,
	F14	Sean D. CONNER et al., "Regulated portals of entry into the cell", NATURE, Vol. 422, March 6, 2003, pp. 37—44.	
	F15	Esteban VEIGA et al., "The role of clathrin-dependent endocytosis in bacterial internalization", TRENDS IN CELL BIOLOGY, VOL. 16, NO. 10, pp. 499-504.	t
	F16	Mickey PENTECOST et al., "Listeria monocytogenese Internalin B Activates Junctional Endocytosis to Accelerate Intestinal Invasion", PLoS Pathogens, Vol. 6, Issue 5, May 2010, document e1000900, 15 pgs.	T
	F17	Jennifer A. MACDIARMID et al., "Bacterially Derived 400 nm Particles for Encapsulation and Cancer Cell Targeting of Chemotherapeutics", Cancer Cell 11, May 2007, pp. 431-445.	Γ
	F18	Sharon I. MICHAEL et al., "Strategies to achieve targeted gene delivery via the receptor-mediated endocytosis pathway", Gene Therapy (1994) 1, pp. 223-232.	Г
	F19	Richard J. CRISTIANO et al., "Strategies to accomplish gene delivery via the receptor-mediated endocytosis pathway", Cancer Gene Therapy, Vol. 3, No. 1, 1996, pp. 49—57.	Γ
	F20	Robert M. SMITH et al., "Hepatocyte-directed Gene Delivery by Receptor-mediated Endocytosis", Seminars in Liver Disease, Vol. 19, No. 1, 1999, pp. 83—92.	
	F21	Javier PIZARRO-CERDÁ et al., "Bacterial Adhesion and Entry into Host Cells", Cell 124, February 24, 2006, pp. 715—727.	
			L
			_
			L
			H
			+
			H
			+

Examiner	Date	
Signature	Considered	

EXAMINED, Initial Inference considered, whether or not claims is in notiferance with MISP 660. Daw the through claims in to combination and considered brinds on good has been also considered brinds on good has been also considered brinds on supplication. Application supplication and suggistion considered profits of section (profits). See the Control of Section 1997 of Patient Documents as when using pow or MEPP 601. A Enter Office that issued the obcurrent, bythe ben-defer code (VIPP) Standard ST: 3). 4 For apprecia proceeds the comments, but includes or the year of the regist of the Emperor must procede the sent inturber of the patient documents. St. 4nd of documents they appropriate symbols as indicated on the document under WIPP 0 Standard ST: 16 If possible. 6 Applicant is to place a check mark here If English linguage Translation is attached by the comment of the Control of Standard ST: 16 If possible. 6 Applicant is to place a check mark here If English linguage Translation is attached USFTO by process) an application. Confidentially is governed by 35 U.S. C. 122 and 37 CFR I.1 This collection of the public which is 5 fact by the USFTO by process an application. Confidentially is governed by 35 U.S. C. 122 and 37 CFR I.1 This collection of the completed application from the USFTO in Time will way depending upon the address classes. Any comment of the address of the completed application from the USFTO IT Time will way depending upon the address classes. Any comment of the address of the Control of the Con